NASDAQ : GNTA
Genenta Science S.p.A. — Key statistics
Healthcare · Biotechnology · Italy
Last price 0.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 29.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 29.81M |
| Enterprise Value | 5.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 48.22M |
| Shares Change (YoY) | +7.86% |
| Shares Change (QoQ) | +10.04% |
| Owned by Insiders (%) | 11.40% |
| Owned by Institutions (%) | 1.95% |
| Float | 38.38M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.16 |
| Quick Ratio | 13.90 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -38.03% |
| Return on Assets (ROA) | -17.67% |
| Return on Invested Capital (ROIC) | -19.68% |
| Return on Capital Employed (ROCE) | -22.18% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$851,868 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -79.46% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 36.90 |
| Average Volume (20 Days) | 48,323 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 108,069 |
| Short Previous Month | 110,030 |
| Short % of Shares Out | 0.24% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.75M |
| Pretax Income | -7.67M |
| Net Income | -7.67M |
| EBITDA | -7.72M |
| EBIT | -7.75M |
| Earnings Per Share (EPS) | -$0.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 33.05M |
| Total Debt | 8.93M |
| Net Cash | 24.12M |
| Net Cash Per Share | $0.50 |
| Equity (Book Value) | 25.64M |
| Book Value Per Share | 1.09 |
| Working Capital | 32.71M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.70M |
| Capital Expenditures | -8,545 |
| Depreciation & Amortization | 31,471 |
| Net Borrowing | 8.41M |
| Free Cash Flow | -7.71M |
| FCF Per Share | -$0.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.86% |
| Shareholder Yield | -7.86% |
| Earnings Yield | -62.91% |
| FCF Yield | -25.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |